Today: 20 March 2026
Subscribe
Browse Category

NYSE:CNDT 30 October 2025 - 27 December 2025

NYC Subway’s New ‘Modern Fare Gates’ Roll Out: AI Cameras, Blasting Alarms, and a Viral Broadway–Lafayette Incident

NYC Subway’s New ‘Modern Fare Gates’ Roll Out: AI Cameras, Blasting Alarms, and a Viral Broadway–Lafayette Incident

New Cubic-designed subway fare gates with cameras and AI detection began operating this week at Brooklyn’s Atlantic Avenue–Barclays Center station. Earlier pilot gates at Broadway–Lafayette and Third Avenue–138th Street drew complaints for loud alarms during suspected fare evasion. Debate over the new barriers comes as the MTA prepares to raise the base fare to $3.00 in January 2026.
27 December 2025
···
Conduent (CNDT) Q3 2025: $767M Revenue, 5.2% Adjusted EBITDA Margin; Debt Refi Completed as Company Pushes GenAI Across Offerings

Conduent (CNDT) Q3 2025: $767M Revenue, 5.2% Adjusted EBITDA Margin; Debt Refi Completed as Company Pushes GenAI Across Offerings

Conduent reported Q3 2025 revenue of $767 million, missing analyst estimates and down 5% from last year. Adjusted EBITDA margin rose to 5.2%. The company posted a net loss of $46 million, or $0.30 per share. Management reaffirmed full-year guidance and highlighted recent debt refinancing and new AI integrations in government services.
7 November 2025
··
Conduent’s Ticket Machine Revolution Debuts in Italy Amid Data Breach Fallout and Market Buzz

Conduent’s Ticket Machine Revolution Debuts in Italy Amid Data Breach Fallout and Market Buzz

Conduent launched its DOT1 ticket vending machine with SETA S.p.A. in Italy, offering contactless payments and real-time transit updates. The rollout comes as Conduent faces fallout from a data breach that exposed personal data of at least 4.5 million people in the U.S. The company spent $25 million on breach response and is under investigation. Conduent shares trade near $2.50, down 30% over the past year.
30 October 2025
···

Stock Market Today

  • Telix Pharmaceuticals Shares Surge 12.9% After TLX101-Px FDA NDA Resubmission and U.S. Manufacturing Expansion
    March 20, 2026, 1:35 PM EDT. Telix Pharmaceuticals (ASX:TLX) jumped 12.9% following its March 2026 resubmission of the New Drug Application (NDA) for TLX101-Px (Pixclara) to the U.S. FDA. The investigational PET imaging agent targets brain cancer diagnosis, specifically glioma, with no current FDA-approved equivalents in the U.S. The resubmission includes new data after a prior Complete Response Letter and benefits from Orphan Drug and Fast Track designations. Concurrently, Telix's U.S. manufacturing build-out, including cyclotron orders for isotope production, aims to scale supply for future launches. While analysts project revenue of A$1.2 billion and earnings of A$111 million by 2029, the company faces risks from heavy R&D and manufacturing investments that may pressure margins if commercialization stalls. Investors are weighing potential near-term catalysts against execution and development uncertainties.
Go toTop